Alliance for Regenerative Medicine Responds to EU Beating Cancer Plan

February 3, 2021

WASHINGTON, DC and BRUSSELS, BELGIUM

The Alliance for Regenerative Medicine (ARM) – the ‘global voice’ of the regenerative medicine and advanced therapies sector – applauds the EU Beating Cancer Plan’s identification of Advanced Therapy Medicinal Products (ATMPs) as part of a comprehensive cancer solution. ATMPs include cell and gene therapies that have already revolutionized the treatment of some aggressive forms of blood cancers and hold great promise for addressing other types of cancer.


ARM Statement on the Trump Administration's Interim Final MFN Rule

January 26, 2021

Washington, DC


ARM Responds to EU Pharmaceutical Strategy

November 25, 2020

Washington, DC

The EU Pharmaceutical Strategy recognizes cell and gene therapies as ‘major milestones’ of progress in healthcare, which can durably treat or even cure the most challenging diseases. We are reviewing today’s strategy document in detail and believe that innovative regulatory and payment policies are crucial to ensuring patient access to these transformative therapies. We look forward to engaging with the European Commission and other stakeholders to develop a conducive, holistic environment for advanced therapies and the life-changing benefits they bring to patients.


ARM Statement on the Trump Administration's Interim Final Rule on Drug Pricing

November 20, 2020

Washington, DC

Cell, gene, and tissue-based therapies are the future of medicine, with the potential to durably treat or even cure the most challenging diseases. The administration’s ‘Most Favored Nation’ Interim Final Rule could threaten innovation in regenerative medicine. If the administration is concerned about clinical outcomes and high expenditures, policymakers should embrace innovative payment models, including outcomes-based agreements that reward scientific investment when therapies work and patients’ conditions improve.